Welcome to our dedicated page for SI-BONE news (Ticker: $SIBN), a resource for investors and traders seeking the latest updates and insights on SI-BONE stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SI-BONE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SI-BONE's position in the market.
Rhea-AI Summary
SI-BONE, a medical device company dedicated to musculoskeletal disorders, will be presenting at the 2024 BofA Securities Healthcare Conference. Investors can join the fireside chat on May 14, 2024, at 2:20 p.m. Eastern Time. The webcast will be accessible for replay for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
-
Rhea-AI Summary
SI-BONE, Inc. (SIBN) will report its first-quarter 2024 financial results on May 6, 2024. The company focuses on musculoskeletal disorders of the sacropelvic anatomy. The conference call will be held at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors can register to listen to the call via a provided link. The webcast will be available on the company's website for replay for at least 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
-
Rhea-AI Summary
SI-BONE, Inc. (SIBN) will be participating in the Barclays 26th Annual Global Healthcare Conference. They will host a fireside chat on March 12, 8:30 a.m. EST. Investors can register to listen to the conference call online. The webcast will be available on the company's website for replay for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
Rhea-AI Summary
SI-BONE, Inc. (SIBN) reported strong financial results for Q4 and FY 2023, with worldwide revenue up by ~22% and ~31% respectively. The company achieved gross margins of ~74% in Q4 and ~79% in FY 2023. Despite an increase in operating expenses, the net loss improved by ~2% in Q4 and ~29% for the year. Adjusted EBITDA loss declined by ~16% in Q4 and ~48% for FY 2023. Cash and equivalents stood at ~$166 million as of December 31, 2023. The company expects a 17% to 19% year-over-year revenue growth for 2024, with a gross margin of ~78% and operating expenses growth of ~9%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.53%
Tags
-
Rhea-AI Summary
SI-BONE, Inc. (SIBN) will report financial results for Q4 and full year 2023 on February 26, 2024. The company specializes in medical devices for musculoskeletal disorders. A conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET, with the webcast available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
-
Rhea-AI Summary
SI-BONE, Inc. (SIBN) announces FDA 510(k) premarket clearance for the iFuse Bedrock Granite Implant System, expanding its indication in pediatric patients and application in the S1 trajectory. The Granite implant provides sacroiliac fusion and sacropelvic fixation, with a smaller 9.5 mm diameter option. The system was also awarded Breakthrough Device Designation and New Technology Add-on Payment. Medical professionals express excitement about the potential benefits of the new implant system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.31%
Tags
Rhea-AI Summary
SI-BONE, Inc. (SIBN) announces preliminary and unaudited revenue for the fourth quarter and full year 2023, with worldwide revenue expected to be in the range of $138.5-138.7 million, representing growth of approximately 30% compared to the prior year period. U.S. revenue is expected to be in the range of $130.5-$130.6 million, with cash and marketable securities expected to be approximately $166.0 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.06%
Tags
-
Rhea-AI Summary
SI-BONE, Inc. (Nasdaq: SIBN) announced its participation in the Piper Sandler Healthcare Conference in New York. The company's management will host a fireside chat on November 28, 2023, at 3:30 p.m. ET. Interested investors can register to listen to the conference call via a provided link. The webcast will be available on the company's website and archived for at least 90 days after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
-
News
Rhea-AI Summary
SI-BONE, Inc. (Nasdaq:SIBN) reported financial results for Q3 2023, with record worldwide revenue of $34.0 million, representing approximately 29% growth over the same period in 2022. U.S. revenue reached $32.3 million, a 31% increase. Gross margin was approximately 79%. The company also received a patent for a crucial technology and surpassed 90,000 procedures performed worldwide. Annual guidance has been increased to $136 million - $137 million, implying annual growth of 28%-29%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
Rhea-AI Summary
SI-BONE, Inc. will be participating in the Jefferies London Healthcare Conference on November 15, 2023. The company will host a fireside chat at 4:00 a.m. ET / 1:00 a.m. PT. Investors can register to listen to the conference call via a provided link. The webcast will be available on the company's website and archived for at least 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
SI-BONE, Inc.
Nasdaq:SIBN
SIBN Rankings
SIBN Stock Data
585.10M
37.81M
2.38%
98.43%
5.95%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
SANTA CLARA
About SIBN
si-bone® is focused on helping patients in one of the most under-served, under-diagnosed, and under-treated areas in orthopedics, the sacroiliac (si) joint. si-bone developed an innovative, patented implant to fuse the si joint. the ifuse implant system® provides a less invasive alternative to traditional sacroiliac (si) joint fusion surgery and has been used in over 25,000 procedures to date. the company is managed by an experienced team of executives from kyphon, medtronic, inbone, saint francis and several start up orthopedic and spine companies. the ifuse implant system is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. this includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. there are potential risks associated with the ifuse implant system. it may not be appropriate for al